Related Experiment Video
Updated: Sep 7, 2025
07:02
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
7.4K
FOXP4-AS1 Inhibits Papillary Thyroid Carcinoma Proliferation and Migration Through the AKT Signaling Pathway
Xue Luo1,2, Qingjun Gao2, Tian Zhou3
1Clinical Medical College, Guizhou Medical University, Guiyang, China.
Frontiers in Oncology
|June 20, 2022
Summary
Long non-coding RNA FOXP4-AS1 acts as a tumor suppressor in papillary thyroid carcinoma (PTC). Upregulated FOXP4-AS1 inhibits PTC progression by regulating the AKT signaling pathway and its host gene FOXP4.
Area of Science:
- Endocrinology
- Molecular Biology
- Oncology
Background:
- Papillary thyroid carcinoma (PTC) is a common endocrine malignancy.
- Long non-coding RNAs (lncRNAs) play critical roles in PTC development, influencing proliferation, resistance, invasion, and stemness.
- The specific role of FOXP4-AS1 in PTC remains largely unexplored.
Purpose of the Study:
- To investigate the role and mechanism of lncRNA FOXP4-AS1 in papillary thyroid carcinoma.
- To determine the expression levels and clinical significance of FOXP4-AS1 in PTC patients.
Main Methods:
- Analysis of FOXP4-AS1 expression in PTC tissues and cell lines.
- Correlation analysis between FOXP4-AS1 expression and clinical parameters in TCGA cohort.
- Functional assays (in vitro and in vivo) to assess the impact of FOXP4-AS1 on PTC cell behavior.
- Mechanism studies involving the AKT signaling pathway and the host gene FOXP4.
Main Results:
- FOXP4-AS1 was found to be downregulated in PTC tissues and cell lines.
- Higher FOXP4-AS1 expression correlated with a better disease-free interval and was linked to clinical stage, T stage, N stage, and extraglandular invasion.
- Upregulated FOXP4-AS1 suppressed PTC cell proliferation, migration, and promoted apoptosis, while its downregulation promoted PTC progression.
- FOXP4-AS1 inhibits PTC tumorigenesis via the AKT signaling pathway and negatively regulates its host gene FOXP4.
Conclusions:
- FOXP4-AS1 functions as a tumor suppressor in papillary thyroid carcinoma.
- FOXP4-AS1 inhibits PTC progression by modulating the AKT signaling pathway and FOXP4 expression.
- FOXP4-AS1 represents a potential therapeutic target for PTC treatment.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
01:19Interactions Between Signaling Pathways
6.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
01:20The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K